Acquisition of APIRx
For personal use only
Benefits of the APIRx Acquisition
06.
Over-the-counter (OTC) patented CBD chewable tablet relevant
to a range of ailments being planned for the CheWell
high-bioavailability oral mucosa dosage form.
Therapeutic Goods Administration (TGA) limits on daily CBD dosage
for OTC cannabinoid products necessitate high bioavailability formulation
such as CheWell being acquired by Incannex.
Generic CBD oils have low bioavailability, due to low solubility, gastrointestinal
loss, first pass metabolism and potentially low effectiveness.
Opportunity to leverage favourable phase 1 and phase 2 trial data to expedite
the TGA approval process.
07.
APIRX management team have extensive expertise in multiple aspects
of cannabinoid development including: extraction, formulation,
IP generation and clinical/regulatory development.
Extensive international network of academic and industry partnerships
to accelerate development of all drug candidates.
Incannex
08.
All research and
development of APIRX
assets in Australia will
be eligible for the R&D
tax rebate of 43.5%
for R&D spend.
Shareholder PresentationView entire presentation